The Francis Crick Institute, the UK's newest biomedical research facility, and GSK, the UK's largest pharmaceutical company, are to partner on an open innovation collaboration exploring new avenues of medical research and drug discovery across a broad range of diseases, with a view to achieving breakthroughs in the understanding of human disease.
This is the first collaboration to be established between the Crick and a pharmaceutical company.
Teams of scientists from each organisation will work side-by-side in integrated teams at the Crick's world-leading centre of biomedical research in the heart of London and GSK's global R&D hub in Stevenage. The close proximity of these two sites and the institutions' complementary areas of expertise will create a fertile ground for collaborative, innovative research – exposing scientists to new ways of thinking and building capability within each organisation. Increased interactions between Crick and GSK scientists will benefit both sides, introducing new ways of working and stimulating the development of novel approaches to problems. GSK and the Crick believe that this fluid interchange of skills and ideas could lead to significant discoveries in the basic scientific understanding of human disease, which could ultimately improve the success rate for discovering new medicines.
One of the greatest challenges in developing new medicines is knowing where to start: scientists still have much to learn about the underlying biology of many diseases, which makes developing effective drug discovery programmes very difficult. Improving scientific understanding at this early stage of research is fundamental to improving researchers' ability to develop innovative new treatments for patients.
The GSK-Crick open science collaboration will combine the specialised disease biology knowledge of the Crick's scientists with the pharmaceutical R&D expertise of GSK scientists, opening up possibilities for scientific discovery that would not be possible for each partner working alone. Together, these world-leading researchers will conduct biological research projects focused on learning more about how diseases take hold in the body and how they could best be treated, which in turn is expected to result in increased efficiency and reduced attrition in R&D.
David Roblin, Chief Operating Officer & Director of Scientific Translation at the Francis Crick Institute, said: "This truly represents a landmark agreement in open science. In the Crick we aim to have industrial scientists embedded in our laboratories and fully integrated with our existing scientific groups. Together the scientists will accelerate breakthroughs in the understanding of human health and disease. GSK is an outstanding partner to commence this effort and I am excited to see what we deliver together.
GSK's President of Pharmaceuticals R&D, Patrick Vallance, said: "As a company with deep research roots in the UK, we're enormously proud of this country's vibrant biosciences community and the cutting-edge biomedical research that takes place here. That's why we continue to invest a quarter of our R&D spend in the UK and have collaborations in place with some of the country's top research institutions, which rank among the best in the world.
"The Francis Crick Institute combines some of the world's best scientific minds and promises to firmly cement the UK as a global leader in life sciences research. We're thrilled to be the first industry partner of this dynamic organisation and believe that by working alongside one another, combining our unique strengths, we'll be well-placed to make game-changing advances in our understanding of human disease, which will ultimately improve our ability to make new medicines."
In the spirit of open innovation, research findings from the collaboration will be shared with the broader scientific community, via joint publication in peer-reviewed journals. This will enable important discoveries to be applied across the research community, maximising the potential for the collaboration to progress scientific understanding and accelerate the development of treatments for patients.
GSK and the Crick will contribute in-kind resources, including lab space and the scientific expertise of 20 staff to the collaboration. GSK will also provide important research tools to the collaboration, including access to its non-development compound library, key antibodies, reagents and technologies, which will be used to address key questions in disease biology.
A number of projects within this collaboration exploring diseases including HIV, malaria and cancer are expected to start in 2015. This will build up to a steady state of 10-15 projects in 2016. The ongoing nature of the Crick-GSK collaboration is expected to foster strong links between the organisations, as well as providing an excellent channel for the training and development of talented staff.
GSK – one of the world's leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com.
The Francis Crick Institute is a new and distinctive biomedical research institute. Its purpose built laboratory in the King's Cross area of London will open at the end of 2015. The institute's work - which is already underway at the Crick's Clare Hall, Lincoln's Inn Fields and Mill Hill laboratories - will help to understand why disease develops. We will find new ways to diagnose, prevent and treat a range of illnesses − such as cancer, heart disease and stroke, infections and neurodegenerative diseases. We will bring together outstanding scientists from all disciplines, carrying out research that will help improve the health and quality of people's lives, and keeping the UK at the forefront of medical innovation. The Francis Crick Institute is a charity supported by the Medical Research Council, Cancer Research UK, the Wellcome Trust, UCL (University College London), Imperial College London and King's College London.
The Francis Crick Institute enquiries:
Peter Zarko-Flynn +44 7525 053795
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Risk factors' in the company's Annual Report on Form 20-F for 2014.